Home/Filings/3/0001876264-25-000004
3//SEC Filing

LSP 7 Cooperative UA 3

Accession 0001876264-25-000004

CIK 0002044725other

Filed

Nov 4, 7:00 PM ET

Accepted

Nov 5, 8:12 PM ET

Size

8.0 KB

Accession

0001876264-25-000004

Insider Transaction Report

Form 3
Period: 2025-11-05
Holdings
  • Series C Preferred Stock

    Common Stock (773,069 underlying)
  • Series B Preferred Stock

    Common Stock (646,587 underlying)
  • Series A Preferred Stock

    Common Stock (1,947,477 underlying)
Footnotes (4)
  • [F1]The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.9557 basis and has no expiration date. Upon the closing of the Issuer's initial public offering ()"IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.
  • [F2]The securities are directly held by LSP 7 Cooperatief U.A., of which, LSP 7 Management B.V. is the sole director. The managing directors of LSP 7 Management B.V. are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe.
  • [F3]The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
  • [F4]The Series C Preferred Stock is convertible into Common Stock on a 1-for-8.518 basis and has no expiration date. Upon the closing of the Issuer's IPO, all shares of Series C Preferred Stock will be converted into shares of Common Stock of the Issuer.

Issuer

Evommune, Inc.

CIK 0002044725

Entity typeother
IncorporatedNetherlands

Related Parties

1
  • filerCIK 0001876264

Filing Metadata

Form type
3
Filed
Nov 4, 7:00 PM ET
Accepted
Nov 5, 8:12 PM ET
Size
8.0 KB